WallStSmart

AbbVie Inc (ABBV)vsSight Sciences Inc (SGHT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 74581% more annual revenue ($66.01B vs $88.39M). ABBV leads profitability with a 15.7% profit margin vs -32.1%. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

SGHT

Avoid

27

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 6.0
Piotroski: 5/9Altman Z: -3.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-87.6%)

Margin of Safety

-87.6%

Fair Value

$157.25

Current Price

$294.64

$137.39 premium

UndervaluedFair: $157.25Overvalued
SGHTUndervalued (+33.3%)

Margin of Safety

+33.3%

Fair Value

$8.29

Current Price

$10.59

$2.30 discount

UndervaluedFair: $8.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$520.47B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

SGHT1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
25.2%8/10

Revenue surging 25.2% year-over-year

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

SGHT4 concerns · Avg: 3.3/10
Price/BookValuation
11.9x4/10

Trading at 11.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$601.92M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-57.8%2/10

ROE of -57.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : SGHT

The strongest argument for SGHT centers on Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.

Bear Case : SGHT

The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

ABBV profiles as a mature stock while SGHT is a growth play — different risk/reward profiles.

SGHT carries more volatility with a beta of 2.40 — expect wider price swings.

SGHT is growing revenue faster at 25.2% — sustainability is the question.

ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (77/100 vs 27/100), backed by strong 15.7% margins and 10.3% revenue growth. SGHT offers better value entry with a 33.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Sight Sciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.

Want to dig deeper into these stocks?